Financial Data and Key Metrics Changes - Neogen reported revenue of approximately $209 million for Q1 FY 2026, reflecting a year-over-year increase of 0.3% on a core basis [12][15] - Adjusted EBITDA was $35.5 million, representing a margin of 17%, impacted by lower revenue, higher tariff costs, and increased operating expenses [21][22] - Free cash flow for the quarter was an outflow of $13 million, an improvement of $43 million compared to the prior year [22][23] Business Line Data and Key Metrics Changes - Food safety segment revenues were $152 million, down 4.6% year-over-year, with a core decline of 1.7% [15][16] - Animal safety segment revenues were $57 million, a decline of 0.8%, but core revenue grew by 5.8% [17] - Petrifilm experienced a mid-single-digit decline in revenue, attributed to distributor inventory adjustments rather than a change in underlying demand [12][16] Market Data and Key Metrics Changes - Core revenue growth was mixed across regions, with LATAM showing mid-single-digit growth, while the U.S. and Canada had low single-digit growth [18] - The APAC region faced challenges, particularly in China and ASEAN countries, impacting overall performance [19] Company Strategy and Development Direction - The company aims to drive top-line growth, right-size its cost base, and reinvigorate innovation without a major strategic overhaul [5][7] - A focus on optimizing the product portfolio for market share gains and profitability, including targeted price increases, is underway [8] - The addition of a Chief Commercial Officer is being pursued to enhance global commercial leadership [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's potential for growth despite current execution challenges, emphasizing the need for improved operational efficiency [4][29] - The CEO highlighted the importance of regaining market share and improving customer relationships as key priorities moving forward [26][39] Other Important Information - The company executed a global headcount reduction of approximately 10%, aiming for annualized savings of about $20 million [7][24] - The divestiture of the cleaners and disinfectants business generated approximately $115 million in net proceeds, which was used to pay down debt [22] Q&A Session Summary Question: Can you discuss the strengths of Neogen and the challenges faced? - The CEO confirmed the company's strong market position and employee dedication, while acknowledging execution challenges that have led to market share losses [33][34] Question: How will the company regain market share with unique products? - The CEO outlined three strategies: leveraging a broad product portfolio, exploring underpenetrated markets, and enhancing execution within the commercial organization [38][39] Question: What is the expected progression of EBITDA margins throughout the year? - The CFO indicated that EBITDA margins are expected to improve as the year progresses, driven by volume increases and cost structure benefits [40] Question: What is the timeline for outlining the company's vision post-CEO transition? - The CEO mentioned that more details on the company's vision will be shared in early 2026, focusing on quick wins and critical projects [44] Question: Can you clarify the $6 million in sample collection costs? - The CFO explained that these costs are related to scrap and quality flags, indicating that the company is currently selling the product at a loss [72] Question: How will the company manage headcount and turnover during this transition? - The CEO emphasized the need for continuous evaluation of resources and the importance of re-engaging employees to drive growth [76][77] Question: Will there be additional divestitures beyond the genomics process? - The CEO confirmed that the company is always in portfolio review mode and will continue to assess product lines for optimization [85][87]